Sentinel Lymphadenectomy in Cervical Cancer Using Near Infrared Fluorescence from Indocyanine Green Combined with Technetium-99m-nanocolloid
Overview
Pharmacology
Authors
Affiliations
Objective: Sentinel diagnostic in cervical cancer is performed using Technetium-99m-nanocolloid as a radioactive marker with or without patent blue. In the last years, indocyanine green has been evaluated for sentinel diagnostic in different tumor entities. Indocyanine green is a fluorescent molecule which emits a light signal in the near infrared band after excitation. Our study aims to evaluate indocyanine green compared to the gold standard Tc-99m-nanocolloid.
Materials And Methods: We included patients with early cervical cancer up to FIGO stage IIA with clinically node-negative pelvic sites and the indication for nodal staging in this prospective trial. Sentinel diagnostic was carried out using Tc-99m-nanocolloid, indocyanine green and patent blue. We examined each pelvic site for light signals from the near infrared band, for radioactivity and for blue staining. A sentinel lymph node was defined as a Tc-99m-nanocolloid positive lymph node. All sentinel lymph nodes and all additional blue or fluorescent lymph nodes were excised and tested; then sent to histologic examination.
Results: Thirty-three patients were included in which we found 211 Tc-99m-nanocolloid-positive sentinel lymph nodes in 66 pelvic sites. Two hundred and seven of these lymph nodes were positive for indocyanine green, too, giving a sensitivity of 98.1% (95%CI 94.9-99.4%) compared to Tc-99m-nanocolloid. One hundred and sixty additional lymph nodes showed indocyanine green fluorescence but no Tc-99m-positivity, so that the sensitivity was 79.6% (95%CI 76.6-82.3%). In one patient, a pelvic site was only identified to be tumor infiltrated due to an ICG-positive, but Tc-99m-negative lymph node.
Conclusion: Our results show that indocyanine green is a promising approach for pelvic sentinel identification in cervical cancer. ICG has a similar sensitivity as radioactive Tc-99m-nanocolloid and may enhance both patient safety and surgeons' comfort. Lasers Surg. Med. 50:994-1001, 2018. © 2018 Wiley Periodicals, Inc.
Manning-Geist B, Obermair A, Broach V, Leitao M, Zivanovic O, Abu-Rustum N Int J Gynecol Cancer. 2024; 34(3):416-420.
PMID: 38438171 PMC: 10962647. DOI: 10.1136/ijgc-2023-004583.
Ploger R, Condic M, Ralser D, Ploger H, Egger E, Otten L J Clin Med. 2023; 12(18).
PMID: 37762865 PMC: 10531937. DOI: 10.3390/jcm12185923.
Wit E, KleinJan G, Berrens A, van Vliet R, van Leeuwen P, Buckle T Eur J Nucl Med Mol Imaging. 2023; 50(9):2861-2871.
PMID: 37036490 DOI: 10.1007/s00259-023-06191-7.
Cassinotti E, Al-Taher M, Antoniou S, Arezzo A, Baldari L, Boni L Surg Endosc. 2023; 37(3):1629-1648.
PMID: 36781468 PMC: 10017637. DOI: 10.1007/s00464-023-09928-5.
Baeten I, Hoogendam J, Braat A, Veldhuis W, Jonges G, Jurgenliemk-Schulz I BMJ Open. 2022; 12(9):e061829.
PMID: 36100304 PMC: 9472172. DOI: 10.1136/bmjopen-2022-061829.